Educational content only. Nothing here is investment advice, a solicitation, or an offer. Ideas are AI-generated. Past performance does not predict future results. Full disclosures →
LIVE Loading pipeline status…

CARL · Carlsmed, Inc. — research history

CARL Carlsmed, Inc. ↗ Yahoo
Loading live quote…

Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on CARL. Public so users can audit, AI can re-reference. Live price refreshes every 60s.

1 events · 1 investigation(s) · 0 published idea(s) · 0 lesson(s)

About CARL · Carlsmed, Inc.

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

IndustryHealth Information ServicesSectorHealthcareEmployees127HQCarlsbad, CA, United StatesWebcarlsmed.com ↗

Live Quote

Chart Signal · 1yr SELL conf 3/5 · score -6
Bear$11.8911.3%
Fair$13.22+23.7%
Bull$23.00+115.2%

SELL (score -6) · 12-1 mom -12.8% · RSI 49.2 · above_50_only · -37.1% from high

Targets blend Wall Street consensus (5 analysts: low $16.00 / mean $18.40 / high $23.00) with chart-derived floors and ceilings.

1-Year Chart · RSI · MACD

Loading 1-year chart…

Research Timeline

Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.

Jun 22, 2026scoutno_anomalyconf 4/522 tool calls · 16mdebug ⤴

The investigation trigger (4 Form 4 filings in 14 days) is confirmed but materially misleading. All four recent filings are RSU compensation grants to outside directors — transaction code 'A' at $0 consideration — not open-market purchases or sales that signal insider conviction. The CEO sold shares in March 2026 via a cashless option exercise (selling to cover cost basis and taxes), not a discretionary purchase of additional shares. There is no options market for CARL, making every structured-income or spread thesis unexecutable. Revenue growth of 86% YoY (Q1 2026: +58%) is genuine and the cervical platform NTAP reimbursement ($21,125 add-on) from CMS effective Oct 2025 is a real catalyst for FY26 guidance expansion to $72-77M. However, with no positive earnings path visible in any near-term window, negative forward P/E, no IV premium available, and RSI neutral-zone (40.8), there is nothing the pipeline can actually trade here.

For AI Agents

Structured JSON of this page's history is at /api/research/CARL.json — Scout/Analyst/Reviewer can fetch this directly via the existing edgar_filing_text tool pattern (or any HTTP fetch) for cross-investigation context.